Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1 . Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organsIn VivoThe metabolic pathway of Allisartan isoproxil is relatively simple, and Allisartan isoproxil is completely and directly converted to EXP-3174 by esterase during gastrointestinal absorption . Allisartan isoproxil/t(20, 80 and 320 mg/kg/day; po; for 26 weeks) decreases body weight at 80-320 mg/kg/day dose, in Sprague-Dawley rats . Allisartan isoproxil/t(30 mg/kg/day; po in diet; for 55 weeks) significantly decreases stroke-related death and prolongs lifespan in stroke-prone renovascular hypertensive rats (RHR-SP). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Femal and male Sprague-Dawley rats Dosage: 20, 80 and 320 mg/kg Administration: Result: Decreased body-weight gain at 320 mg/kg/day in both sexes as well as at the 80-mg/kg/day dose in females. Decreased erythrocyte parameters in males, and decreased heart weight and exacerbation of chronic progressive nephropathy (CPN) severity in males at 80 and 320 mg/kg/day.Form:SolidIC50& Target:Angiotensin II Type 1. Molecular Formula: C27H29ClN6O5 Molecular Weight: 553.01 PubChem CID: 24748496 Isomeric SMILES: CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCOC(=O)OC(C)C)Cl
- UPC:
- 51171945
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- A646447-10mg
- CAS:
- 947331-05-7
- Product Size:
- 10mg
